KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2016 - 2018)

Emergent BioSolutions (EBS) has 8 years of Gains from Sales and Divestitures data on record, last reported at $427610.0 in Q4 2018.

  • For Q4 2018, Gains from Sales and Divestitures rose 0.89% year-over-year to $427610.0; the TTM value through Dec 2018 reached $427610.0, up 0.89%, while the annual FY2018 figure was $427610.0, 0.89% up from the prior year.
  • Gains from Sales and Divestitures reached $427610.0 in Q4 2018 per EBS's latest filing, up from $423840.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $427610.0 in Q4 2018 and bottomed at $298489.0 in Q1 2014.
  • Average Gains from Sales and Divestitures over 5 years is $384188.2, with a median of $403992.0 recorded in 2017.
  • Peak YoY movement for Gains from Sales and Divestitures: increased 19.5% in 2015, then fell 1.0% in 2016.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $361010.0 in 2014, then rose by 17.04% to $422515.0 in 2015, then dropped by 0.45% to $420599.0 in 2016, then increased by 0.77% to $423840.0 in 2017, then grew by 0.89% to $427610.0 in 2018.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $427610.0 in Q4 2018, $423840.0 in Q4 2017, and $413752.0 in Q3 2017.